Literature DB >> 10147055

The Australian Guidelines for subsidisation of pharmaceuticals.

D A Henry.   

Abstract

Mesh:

Substances:

Year:  1992        PMID: 10147055     DOI: 10.2165/00019053-199202050-00010

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  4 in total

1.  The Australian Guidelines for subsidisation of pharmaceuticals: the road to cost-effective drug prescribing?

Authors:  M Johannesson
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

2.  Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.

Authors:  D Henry
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

3.  Potential for bias in economic analyses.

Authors: 
Journal:  N Engl J Med       Date:  1991-11-07       Impact factor: 91.245

4.  Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

Authors:  A L Hillman; J M Eisenberg; M V Pauly; B S Bloom; H Glick; B Kinosian; J S Schwartz
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

  4 in total
  3 in total

1.  Indirect costs in economic studies: confronting the confusion.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

2.  Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America.

Authors:  K Clemens; R Townsend; F Luscombe; J Mauskopf; J Osterhaus; J Bobula
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

3.  Conceptual framework for standard economic evaluation of physical activity programs in primary prevention.

Authors:  Silke B Wolfenstetter
Journal:  Prev Sci       Date:  2011-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.